| Sonstiges: |
- Nachgewiesen in: USPTO Patent Grants
- Sprachen: English
- Patent Number: 7,172,873
- Publication Date: February 06, 2007
- Appl. No: 10/112648
- Application Filed: March 28, 2002
- Assignees: Heska Corporation (Loveland, CO, US)
- Claim: 1. A method to detect early renal disease in a canid, a feud or an equid comprising: (a) obtaining a urine sample from said canid, feud or equid; and (b) determining the amount of albumin in said sample, wherein an amount of albumin in a range from about 10 μg/ml to about 300 μg/ml in the sample, when the specific gravity of the sample is normalized to 1.010, is indicative of early renal disease.
- Claim: 2. The method of claim 1 , wherein the method is repeated at least once.
- Claim: 3. The method of claim 1 , wherein the method is repeated at least once to monitor a disease or the effect of a therapy.
- Claim: 4. The method of claim 1 , wherein the method is performed once.
- Claim: 5. The method of claim 1 , wherein the determination of the amount of albumin in the sample is performed at room temperature.
- Claim: 6. The method of claim 1 , wherein the amount of albumin in the sample is determined by: (a) contacting the sample with an albumin-binding compound to form an albumin-compound complex; (b) detecting the albumin-compound complex; and (c) assessing the amount of albumin present in the sample from the amount of albumin-compound complex detected.
- Claim: 7. The method of claim 6 , wherein the albumin-binding compound is an anti-albumin antibody.
- Claim: 8. The method of claim 6 , wherein the albumin-binding compound is an anti-albumin antibody which recognizes albumin from an animal selected from the group consisting of canids, felids and equids.
- Claim: 9. The method of claim 1 , wherein the amount of albumin in the sample is determined using an assay selected from the group consisting of an enzyme-linked immunoassay, a radioimmunoassay, a fluorescence immunoassay, a chemiluminescent assay, a lateral-flow assay, a dipstick assay, an agglutination assay, a particulate-based assay, an immunoprecipitation assay, an immunodot assay, an immunoblot assay, an immunodiffusion assay, a phosphorescence assay, a flow-through assay, a chromatography assay, a PAGe-based assay, an electronic-sensory assay, a surface plasmon resonance assay and a fluorescence correlation spectroscopy assay.
- Claim: 10. The method of claim 1 , wherein the amount of albumin in the sample is determined using an enzyme-linked immunosorbent assay (ELISA).
- Claim: 11. The method of claim 1 , wherein the amount of albumin in the sample is determined using a single-step assay.
- Claim: 12. The method of claim 1 , wherein the amount of albumin in the sample is determined using a dipstick-based assay.
- Claim: 13. The method of claim 1 , wherein the amount of albumin is determined using an assay that detects albumin in the sample when the amount of albumin is in a range from about 10 μg/ml to about 50 μg/ml when the specific gravity of the sample is normalized to 1.010.
- Claim: 14. The method of claim 1 , wherein the amount of albumin is determined using an assay that detects albumin in the sample when the amount of albumin is about 50 μg/ml when the specific gravity of the sample is normalized to 1.010.
- Claim: 15. The method of claim 1 , wherein the amount of albumin is determined using an assay that detects albumin in the sample when the amount of albumin is about 25 μg/ml when the specific gravity of the sample is normalized to 1.010.
- Claim: 16. The method of claim 1 , wherein the amount of albumin is determined using an assay that detects albumin in the sample when the amount of albumin is about 10 μg/ml when the specific gravity of the sample is normalized to 1.010.
- Claim: 17. The method of claim 1 , wherein the urine sample is obtained from a canid.
- Claim: 18. The method of claim 1 , wherein the urine sample is obtained from a felid.
- Claim: 19. The method of claim 1 , wherein the urine sample is obtained from an equid.
- Claim: 20. The method of claim 1 , wherein the sample is pre-treated prior to determining the amount of albumin.
- Claim: 21. The method of claim 1 , wherein the sample is pre-treated by adjusting the specific gravity.
- Claim: 22. The method of claim 1 , wherein the sample is pre-treated by adjusting the specific gravity to 1.010.
- Claim: 23. A method to identify a canid, a felid or an equid at risk for developing late-stage renal disease comprising: (a) obtaining a urine sample from said canid, felid or equid; and (b) determining the amount of albumin in said sample, wherein an amount of albumin in a range from about 10 μg/ml to about 300 μg/ml in the sample, when the specific gravity of the sample is normalized to 1.010, indicates the animal is at risk for late-stage renal disease.
- Claim: 24. The method of claim 23 , wherein the method is repeated at least once.
- Claim: 25. The method of claim 23 , wherein the method is repeated at least once to monitor a disease or the effect of a therapy.
- Claim: 26. The method of claim 23 , wherein the method is performed once.
- Claim: 27. The method of claim 23 , wherein the determination of the amount of albumin in the sample is performed at room temperature.
- Claim: 28. The method of claim 23 , wherein the amount of albumin in the sample is determined by: (a) contacting the sample with an albumin-binding compound to form an albumin-compound complex; (b) detecting the albumin-compound complex; and (c) assessing the amount of albumin present in the sample from the amount of albumin-compound complex detected.
- Claim: 29. The method of claim 28 , wherein the albumin-binding compound is an anti-albumin antibody.
- Claim: 30. The method of claim 28 , wherein the albumin-binding compound is an anti-albumin antibody which recognizes albumin from an animal selected from the group consisting of canids, feuds and equids.
- Claim: 31. The method of claim 23 , wherein the amount of albumin in the sample is determined using an assay selected from the group consisting of an enzyme-linked immunoassay, a radioimmunoassay, a fluorescence immunoassay, a chemiluminescent assay, a lateral-flow assay, a dipstick assay, an agglutination assay, a particulate-based assay, an immunoprecipitation assay, an immunodot assay, an immunoblot assay, an immunodiffusion assay, a phosphorescence assay, a flow-through assay, a chromatography assay, a PAGe-based assay, an electronic-sensory assay, a surface plasmon resonance assay and a fluorescence correlation spectroscopy assay.
- Claim: 32. The method of claim 23 , wherein the amount of albumin in the sample is determined using an enzyme-linked immunosorbent assay (ELISA).
- Claim: 33. The method of claim 23 , wherein the amount of albumin in the sample is determined using a single-step assay.
- Claim: 34. The method of claim 23 , wherein the amount of albumin in the sample is determined using a dipstick-based assay.
- Claim: 35. The method of claim 23 , wherein the amount of albumin is determined using an assay that detects albumin in the sample when the amount of albumin is in a range from about 10 μg/ml to about 50 μg/ml when the specific gravity of the sample is normalized to 1.010.
- Claim: 36. The method of claim 23 , wherein the amount of albumin is determined using an assay that detects albumin in the sample when the amount of albumin is about 50 μg/ml when the specific gravity of the sample is normalized to 1.010.
- Claim: 37. The method of claim 23 , wherein the amount of albumin is determined using an assay that detects albumin in the sample when the amount of albumin is about 25 μg/ml when the specific gravity of the sample is normalized to 1.010.
- Claim: 38. The method of claim 23 , wherein the amount of albumin is determined using an assay that detects albumin in the sample when the amount of albumin is about 10 μg/ml when the specific gravity of the sample is normalized to 1.010.
- Claim: 39. The method of claim 23 , wherein the urine sample is obtained from a felid.
- Claim: 40. The method of claim 23 , wherein the urine sample is obtained from an equid.
- Claim: 41. The method of claim 23 , wherein the urine sample is obtained from a canid.
- Current U.S. Class: 435/71
- Patent References Cited: 4281061 July 1981 Zuk et al. ; 4804625 February 1989 Morrison et al. ; 5073484 December 1991 Swanson et al. ; 5087575 February 1992 Lau ; 5238924 August 1993 Smith ; 5246835 September 1993 Suzuki et al. ; 5403744 April 1995 Zimmerle ; 5415994 May 1995 Imrich et al. ; 5424193 June 1995 Pronovost et al. ; 5656502 August 1997 MacKay et al. ; 5723441 March 1998 Higley et al. ; 6001658 December 1999 Fredrickson ; 6153392 November 2000 Liao et al. ; 6190878 February 2001 Pierson et al. ; 6214813 April 2001 Zhang et al. ; 2003/0060453 March 2003 Zhang et al. ; 0 198 639 October 1986 ; 0830206 January 2001 ; 04248941 September 1992 ; 202248941 September 1992 ; WO 94/01775 January 1994 ; WO 94/29696 December 1994 ; WO 96/40434 December 1996 ; WO 00/37944 June 2000
- Other References: Burne, et al., 1998, Clinical Science, vol. 95, pp. 67-72. cited by other ; Comper, et al., Feb. 2003, American Journal of Kidney Diseases, vol. 41, No. 2, pp. 336-342. cited by other ; Osicka, et al., Sep. 2000, Diabetes, vol. 49, pp. 1579-1584. cited by other ; Syme, et al., Proceedings 18th ACVIM, Seattle, WA, May 25-28, 2000, Abstraact #97. cited by other ; Bakris, George L., Curr. Opin. in Neph. and Hypertension, 1996, vol. 5, pp. 219-223. cited by other ; Bakris, G. L., J. Clin. Hypertens (Greenwich), 2001, vol. 2, pp. 99-102. cited by other ; Batamuzi, et al., Veterinary Record, 1998, vol. 143, pp. 16-20. cited by other ; Berrut, et al., Clinical Nephrology, 1997, vol. 48, No. 2, pp. 92-97. cited by other ; German, et al., Veterinary Immunology and Immunopathology, 1998, vol. 64, pp. 107-121. cited by other ; Kilaru, et al., Journal of Human Hypertension, 1994, vol. 8, pp. 809-817. cited by other ; Mogensen, C.E., Diabetologia, 1999, vol. 42, pp. 263-285. cited by other ; Pinto-Sietsma, et al., J Am Soc Nephrol, 2000, vol. 11, pp. 1882-1888. cited by other ; Vaden, Proc. 17th ACVIM, 1999, 420. cited by other ; Viberti, GianCarlo, American Journal of Hypertension, Ltd., vol. 7, pp. cited by other ; Watts, Clin. Chem. ,, 1986, vol. 32, No. 8, pp. 1544-1548. cited by other ; Pandjaitan, et cl., 2000, J. Allergy Clin. Immunol., vol. 105 (2 Pt 1), pp. 279-285. cited by other ; Hilger, et al., 1996, Gene, vol. 169, pp. 295-296. cited by other ; Ho et al., 1993, Eur. J. Biochem., vol. 215, pp. 205-212. cited by other
- Assistant Examiner: Davis, Deborah A.
- Primary Examiner: Tate, Christopher R.
- Attorney, Agent or Firm: Heska Corporation
|
